Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus

Eke, Ahizechukwu C.; Eleje, George Uchenna; Eke, Uzoamaka A.; Xia, Yun; Liu, Jiao

doi:10.1002/14651858.cd008545.pub2

Cited by 40 publications

(33 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBV is among these infections. Children born to mothers with +HBsAg and +HBeAg have a 70-90% chance of developing HBV infection, of whom more than 85% will eventually become the chronic carriers of the disease and about 25% of them will die from chronic liver disease or liver cancer (23)(24)(25). Therefore, the correct diagnosis of the possibility of HBV infection in pregnant women or those planning to become pregnant can prevent the occurrence of serious and even deadly infant diseases.…”

Section: Discussionmentioning

confidence: 99%

Development of a New Psychometric Assessment Tool for Predicting Hepatitis B Virus Infection in Pregnant Women

Rostami

Osquee

Mahdavi

et al. 2020

International Journal of Women’s Health and Reproduction Scienc

View full text Add to dashboard Cite

Objectives: Hepatitis B virus (HBV) infection in pregnant women can lead to the development of serious complications in neonates. Therefore, this study aimed to develop a new tool for predicting this infection in pregnant women and to assess the psychometric properties of this scale. Materials and Methods:This methodological study was carried out on 220 pregnant women visiting Al-Zahra and Taleghani hospitals of Tabriz, Iran in 2019. First, the relevant items were formulated and the respective questionnaire was developed and then, the validity (i.e., face, content, and construct) and reliability of the questionnaire were assessed as well. The data were analyzed in SPSS 21 using descriptive statistics, exploratory factor analysis (EFA), dependent t test, and Cronbach alpha coefficient. Results: A 22-item questionnaire was designed and the items were scored using a five-point Likert-type scale (Min=22, Max=120). Finally, the Kaiser-Meyer-Olkin value, Bartlett’s test of the Sphericity value, the internal consistency of the tool based on Cronbach’s alpha coefficient, and the intra-cluster correlation coefficient were 0.801, 4035.810, 0.811, and 0.81, respectively. Conclusions: In general, the present tool can reliably predict HBV infection in pregnant women thus its application is recommended in preventing relevant complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a New Psychometric Assessment Tool for Predicting Hepatitis B Virus Infection in Pregnant Women

Rostami

Osquee

Mahdavi

et al. 2020

International Journal of Women’s Health and Reproduction Scienc

View full text Add to dashboard Cite

show abstract

“…Therefore, several studies have been conducted to clarify whether alternative or additional approaches could help reduce mother-to-child transmission, in particular using antenatal maternal administration of HBIg or antivirals. Several studies that have investigated the effect of immune globulin administered to the mother during pregnancy on HBV transmission to the fetus/newborn have not demonstrated the efficacy of this approach 26. In contrast, maternal antiviral agents administered during the end of pregnancy may decrease the risk of transmission of HBV from a mother to her infant.…”

Section: Antiviralsmentioning

confidence: 99%

<p>Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications</p>

Jourdain

Ngo‐Giang‐Huong

Khamduang

2019

IDR

View full text Add to dashboard Cite

There is currently no cure for hepatitis B chronic infections. Because new hepatitis B infections result mainly from perinatal transmission, preventing mother-to-child transmission is essential to reach by 2030 the goal of hepatitis B elimination set by the World Health Organization. The universal administration of hepatitis B vaccine to all infants, regardless of maternal status, starting with the birth dose, is the cornerstone of the strategy for elimination. Additional interventions, such as hepatitis B immune globulin administered to newborns and antiviral prophylaxis administered to hepatitis B infected pregnant women, may contribute to reaching the goal earlier. Hepatitis B immune globulin may remain out for reach of many pregnant women in low- and middle-income countries due to cost and logistic issues, but antivirals are cheap and do not require a cold chain for distribution. However, it has been observed that some viruses harbor mutations associated with escape from vaccine-elicited antibodies following immunization or administration of hepatitis B immune globulin. Also, resistance associated mutations have been described for several drugs used for treatment of hepatitis B infected patients as well as for the prevention of mother-to-child transmission. Whether these mutations have the potential to compromise the prevention of mother-to-child transmission or future treatment of the mother is a question of importance. We propose a review of important recent studies assessing tenofovir disoproxil fumarate for the prevention of mother-to-child transmission, and provides detailed information on the mutations possibly relevant in this setting.

show abstract

“…Nevertheless, prolongation of antiviral prophylaxis[ 38 ] might be useful at least for women with elevated ALT during pregnancy, since they present a higher risk of post-partum hepatitis flare, as showed by a Chinese study wherein mothers were administered LdT[ 80 ]. With regard to other preventive strategies, unfortunately there is high uncertainty, also due to very low available evidence, upon the potential benefits of the antenatal administration of HBIG, to exploit the maternofoetal diffusion through the placenta, which reaches its peak during the third trimester[ 81 ].…”

Section: Hbv Infection In Pregnancy: From the Perspective Of Foetusesmentioning

confidence: 99%

Current evidence on the management of hepatitis B in pregnancy

Maraolo

Gentile

Buonomo

et al. 2018

WJH

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is one of the main public health problems across the globe, since almost one third of the world population presents serological markers of contact with the virus. A profound impact on the epidemiology has been exerted by universal vaccination programmes in many countries, nevertheless the infection is still widespread also in its active form. In the areas of high endemicity (prevalence of hepatitis B surface antigen positivity > 7%), mother-to-child transmission represents the main modality of infection spread. That makes the correct management of HBV in pregnancy a matter of utmost importance. Furthermore, the infection in pregnancy needs to be carefully assessed and handled not only with respect to the risk of vertical transmission but also with respect to gravid women health. Each therapeutic or preventive choice deserves to be weighed upon attentively. On many aspects evidence is scarce or controversial. This review will highlight the latest insights into the paramount steps in managing HBV in pregnancy, with particular attention to recommendations from recent guidelines and data from up-do-date research syntheses.

show abstract

Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus

Abstract: Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus.

Cited by 40 publications

References 93 publications

Development of a New Psychometric Assessment Tool for Predicting Hepatitis B Virus Infection in Pregnant Women

Development of a New Psychometric Assessment Tool for Predicting Hepatitis B Virus Infection in Pregnant Women

<p>Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications</p>

Current evidence on the management of hepatitis B in pregnancy

Contact Info

Product

Resources

About